Moleculin Biotech (NASDAQ:MBRX – Get Free Report) released its earnings results on Thursday. The company reported ($3.54) EPS for the quarter, missing the consensus estimate of ($1.69) by ($1.85), FiscalAI reports.
Moleculin Biotech Stock Up 3.0%
Shares of MBRX traded up $0.07 during midday trading on Thursday, hitting $2.21. The company had a trading volume of 255,287 shares, compared to its average volume of 166,324. The company’s 50 day moving average price is $2.34 and its 200 day moving average price is $4.81. The stock has a market cap of $11.77 million, a price-to-earnings ratio of -0.07 and a beta of 1.74. Moleculin Biotech has a 52 week low of $1.79 and a 52 week high of $25.00.
Institutional Investors Weigh In On Moleculin Biotech
A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC bought a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 15.52% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Research Report on MBRX
Moleculin Biotech Company Profile
Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.
The company’s pipeline includes multiple product candidates at various stages of development.
Featured Stories
- Five stocks we like better than Moleculin Biotech
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
